Safety and Efficacy of Avapritinib in Chinese Patients With Gastrointestinal Stromal Tumor (GIST) in the Real World
This study is an observational, multicenter, Real-word study to evaluate the safety and clinical efficacy of avapritinib in Chinese subjects with GIST.
Gastrointestinal Stromal Tumors
DRUG: Avapritinib|DRUG: Tyrosine kinase inhibitors other than avapritinib ( imatinib, sunitinib, et al )
Incidence and severity of adverse events(AE) and serious adverse events(SAE)in cohort 1, 2, and 3, AEs were collected from the start of study drug until 30 days after the last dose, SAEs were collected from the date of the informed consent signature until 30 days after the last dose of study drug, up to 3 years.|Dose adjustment of avapritinib in cohort 1, 2, and 3, From the start of study drug until 30 days after the last dose, up to 3 years.
This study is an observational, multicenter, Real-word study to evaluate the safety and clinical efficacy of avapritinib in Chinese subjects with GIST.